Business
BioVie is a clinical-stage company developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease.
BioVie narrowed losses and improved equity, but it remains a no-revenue clinical-stage company with going-concern doubt.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage neuro and liver pipelineNote
- Revenue — No revenue taggedNote
- Loss — Net loss narrowed 45.4%OK
- Cash burn — OCF deficit improved 31.9%OK
- Equity — Equity up 22.6%OK
- Insiders — 1 purchase / 0 sales; $0 valueNote
- Accounting — Forensic screens unavailableNote
Leadership changes
From BIOVIE INC.'s own filings, the day they're filed.
- Steve Gorlin · Directors · departureeff. 2024-07-25
- Amy S. Chappell · Directors · appointment
- Robert Hariri · Directors · departure
Latest filings
- 10-K · Annual report2026-08-13
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-05-11
- 10-Q · Quarterly report2026-02-06
- 8-K · Company announcement2025-11-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BIOVIE INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.